

Thursday, February 12, 2026

Keynote

12:30 - 13:20

Plenary

KN1 - Opening and Keynote Lecture 1 Dirk Busch

OP

OpeningAnnalisa Ruggeri (Milan, Italy)
Maria Themeli (Amsterdam, Netherlands)

12:30 - 12:45

KN1

Keynote Lecture

Dirk Busch (Munich, Germany)

12:45 - 13:20

Physicians Session

13:30 - 15:00

Plenary

PS1 - Acute LeukaemiaJulio Delgado (Barcelona, Spain)
Fabio Ciceri (Milano, Italy)

PS1-1

Paediatric ALL

Franco Locatelli (Rome, Italy, Italy)

13:30 - 13:45

PS1-2

Adult ALL and toxicity prediction models

Valentín Ortiz-Maldonado (Barcelona, Spain)

13:45 - 14:00

PS1-3

T-ALL

Nicola Maciocia (London, United Kingdom)

14:00 - 14:15

PS1-4

AML

Marion Subklewe (Munich, Germany)

14:15 - 14:30

PS1-5

Discussion

14:30 - 15:00

Break

15:00 - 15:40

IT

Coffee Break*Physicians Session*

15:40 - 17:10

Plenary

PS2 - Translational Session I: Keynote Lecture (Carl June) & New frontiers and innovationsMaria Themeli (Amsterdam, Netherlands)
Chiara Bonini (MILAN, Italy)

PS2-1

Keynote Lecture

Carl June (Philadelphia, United States)

15:40 - 16:05

PS2-2

AI use for CAR design

Andrea Schmidts (Munich, Germany)

16:05 - 16:25

PS2-3

Multiplex genetic engineering of immune cells

Josef Leibold (Tuebingen, Germany)

16:25 - 16:45

PS2-4

AI-driven engineered T cell therapies for cancer and autoimmune diseases

Zinaida Good (Stanford, California, United States)

16:45 - 17:05

PS2-5

Conclusions

17:05 - 17:10

Satellite Symposium

17:25 - 18:10

Plenary

SS01 - Satellite Symposium by Bristol Myers Squibb: From Trials to Treatment: CAR T Outcomes Shaping Practice in LBCL and MM

SS01-01	Welcome and Introductions Pere Barba (Barcelona, Spain)	17:25 - 17:30
SS01-02	Real-world evidence driving treatment decisions in LBCL Gabriel Brisou (Marseille, France)	17:30 - 17:45
SS01-03	Multiple myeloma in motion: Clinical perspectives and emerging therapies Paula Rodríguez-Otero (Pamplona, Spain)	17:45 - 18:00
SS01-04	Q&A Session and Adjournment Pere Barba (Barcelona, Spain) Gabriel Brisou (Marseille, France) Paula Rodríguez-Otero (Pamplona, Spain)	18:00 - 18:10

Physicians Session

18:20 - 19:50

Plenary

PS3 - Patient in focus: Delving into CAR-T cell therapy accessibility challenges

Natacha Bolaños (Madrid, Spain)

Solène Clavreul (Nantes, France)

PS3-1	Introduction & framing Solène Clavreul (Nantes, France) Natacha Bolaños (Madrid, Spain)	18:20 - 18:30
PS3-2	Health System & Registry Perspective Christian Chabannon (Marseille, France)	18:30 - 18:50
PS3-3	Access to CAR-T cell therapy saves life since 2014 in Sweden: A national perspective on hurdles and solutions Stephan Mielke (Stockholm, Sweden)	18:50 - 19:10
PS3-4	Panel discussion & Audience Q&A	19:10 - 19:40

Meet-the-Experts

18:30 - 19:30

Menorca

MTE - Meet the Experts

Michael Hudecek (Würzburg, Germany)

Julio Delgado (Barcelona, Spain)

Marion Subklewe (Munich, Germany)

Poster Session

19:55 - 20:55

IT

Welcome Reception & Poster Session

	Prognostic Factors of CAR T Response in Patients with Relapsed or Refractory B-cell Lymphoid Malignancies: A Single Institution Analysis Soo Jung Lee (Suwon, Korea, Republic of)	19:55 - 19:55
	Chimeric Antigen Receptor T Cells Generated from Tissue-homing T Cells to Treat Solid Tumors Eva Pascal (Ghent, Belgium)	19:55 - 19:55
	Engineering Human RBP4-based Molecular Switches for Functional Control of CARs and Transcription Factors Manfred Lehner (Vienna, Austria)	19:55 - 19:55

Persistent Lymphocytosis after Anti-BCMA CAR-T Infusion in a Patient with MMRR	19:55 - 19:55
Miriam Sanchez Escamilla (Santander, Spain)	
Optimizing CAR-T Expansion Conditions for the First Polish Academic Multiple Myeloma Therapy	19:55 - 19:55
Krystian Sarat (Wrocław, Poland)	
A Not too Broken Heart - Axicel for Relapsed Diffuse Large B-cell Lymphoma (DLBCL) with a Background of Dilated Cardiomyopathy	19:55 - 19:55
Gillian Flynn (Southampton, United Kingdom)	
Guillan-Barré-like Syndrome in a Patient Receiving Cilta-cel in Relapsed/Refractory Multiple Myeloma	19:55 - 19:55
Jule Cecilia Artzenroth (Hamburg, Germany)	
Feasibility and Impact of Tailored Bridging Therapy for CAR-T Therapy in Relapsed/Refractory Multiple Myeloma	19:55 - 19:55
Jule Cecilia Artzenroth (Hamburg, Germany)	
CD19-negative Relapse and Treatment-related Mortality after Tisagenlecleucel in B-lymphoblastic Leukemia: A Case Report	19:55 - 19:55
Chi Yen Chen (Taichung City, Taiwan)	
Novel CAR-based Cellular Therapy Targeting Membrane-bound Immunoglobulin E	19:55 - 19:55
Alicja Wojciechowska (Warsaw, Poland)	
Sustained Remission of Acquired Hemophilia A with a CD3xBCMA-directed Bispecific Antibody after Failure of Second Anti-CD19 CAR-T Cell Therapy	19:55 - 19:55
Christian R. Schultze-Florey (Hannover, Germany)	
A Comparison of the Efficacy and Toxicity of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Patients with Large B-cell Lymphoma: A Retrospective, Single-centre Analysis	19:55 - 19:55
Tonia Comino (Zurich, Switzerland)	
A Case of Dual Malignancy - High Risk Multiple Myeloma with Multiple Relapses and Prostate Adenocarcinoma and Trying of CAR-T Based Therapy + Hormone Therapy	19:55 - 19:55
Baishnav Suresh (Bhubaneswar, India)	
Development of a Point-of-Care Manufacturing Facility at an Academic Center in Türkiye: Validation Study for Anti-CD19 CAR-T Cells Using a Closed Cell Processing Platform	19:55 - 19:55
Fatma Visal Okur (Ankara, Turkey)	
Rapid Manufacture and Effective Response of FIT-CD19 CAR-T in Relapsed B-ALL: A Case from NTUH	19:55 - 19:55
Cheng Yeh CHEN (Hsin-Chu, Taiwan)	
First Treatment with the Fully Human MUW-huCD19.1 CAR-T Cell Therapy for Diffuse Cutaneous Systemic Sclerosis	19:55 - 19:55
Nina Worel (Vienna, Austria)	
T and NK Cells on the Move: A Side-by-Side Comparison of Migration Dynamics and Cytotoxic Potential of Naive and Genetically Engineered T and NK Cells	19:55 - 19:55
Alina Moter (Frankfurt am Main, Germany)	
Access to CAR-T Cell Therapy across ALL-IC Relapse Study Group Countries: Results from an International Survey	19:55 - 19:55
Koray Yalcin (İstanbul, Turkey)	
Novel Proximity-labelling Approach to Investigate CAR-based	19:55 - 19:55

Immune Synapse	
Quynh Nhu Nguyen (Ostrava, Czech Republic)	
Engineering of Immunological Synapse through Novel Integrin-based Activation Receptor (IBAR)	19:55 - 19:55
Quynh Nhu Nguyen (Ostrava, Czech Republic)	
Harnessing the Extracellular Matrix to Boost CAR-T Cell Therapy in Solid Tumors	19:55 - 19:55
Giulia D'Accordio (Padova, Italy)	
In vivo Expansion and Persistence of CD33- and CD123-directed Allogeneic CAR-T Cells in Pediatric Relapsed/Refractory AML after HSCT: A Single-center Experience from Russia	19:55 - 19:55
Andrey Russiyanov (Moscow, Russian Federation)	
Combinatorial Strategy for Improved CDH17-CAR T Cell Therapy of Liver Metastases from Colorectal Cancer	19:55 - 19:55
Katia Palmisano (Milan, Italy)	
Place-of-Care Produced Fresh Formulation CD19 CAR-T Cell Therapy in Patients with BTKi-exposed Relapsed or Refractory CD19+ Mantle Cell Lymphoma	19:55 - 19:55
Skirmante Cernauskiene (Vilnius, Lithuania)	
When Remission Is Not Enough: Non-relapse Morbidity after CAR T-cell Therapy	19:55 - 19:55
Catarina Fernandes (Coimbra, Portugal)	
Rational Engineering of sdAb-based CAR-T Cells Targeting BCMA Enhances Efficacy and Persistence in Preclinical Models of Multiple Myeloma	19:55 - 19:55
Juan Roberto Rodriguez-Madoz (Pamplona, Spain)	
Translational Development of CD70-directed NanoCAR T-cells for Clear Cell Renal Cell Carcinoma: Efficacy, Safety and Innovation	19:55 - 19:55
Robrecht De Vos (Ghent, Belgium)	
"Real World" Incidence and Characteristics of Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis: A GoCart Coalition Study on behalf of the EBMT ADWP, CTIWP and TCWP	19:55 - 19:55
Matteo Doglio (Milan, Italy)	
CLEC12A-CAR-T Cell Therapy of <i>NPM1m</i> and <i>KMT2A-r</i> AML Can Be Improved by Combination with Menin Inhibition	19:55 - 19:55
Lea R. Knapp (Frankfurt, Germany)	
A Tale of llamas and CARs: V_HH-based CLEC12A-CAR NK Cells for the Treatment of Acute Myeloid Leukaemia	19:55 - 19:55
Lea R. Knapp (Frankfurt, Germany)	
Tyrosine Kinase Inhibitor Therapy Does Not Impair the Quality of Anti-CD19 CAR-T Cell Product	19:55 - 19:55
Apollinariya Bogolyubova (Moscow, Russian Federation)	
Relationship between CAR Spatial Organization and CAR-T Cell Function Revealed by Imaging Flow Cytometry and Transcriptomic Profiling	19:55 - 19:55
Gianluca Rotta (Milan, Italy)	
In-vivo Dynamics of a Novel CD19-directed CAR-T Cell Therapy in Paediatric and Young Adults with Relapsed/Refractory B-acute Lymphoblastic Leukemia (R/R B-ALL)	19:55 - 19:55
Aafreen Ansari (Mumbai, India)	
Restoring Mitochondrial Metabolism of iPSC-derived CAR/TCR-T	19:55 - 19:55

Cells Improves their Anti-tumor Efficacy	
Alexandros Nianias (Amsterdam, Netherlands)	
Long-term Progression-free Survival Benefit with Ciltacabtagene Autoleucel in Standard-risk Relapsed/Refractory Multiple Myeloma	19:55 - 19:55
Paula Rodríguez-Otero (Pamplona, Spain)	
Polymer-based Vectors for Plasmid Delivery: Early Development of a New Non-viral CAR-T Approach	19:55 - 19:55
Sofia Zuffi (Donostia-San Sebastian, Spain)	
Early Single-center Experience in the Treatment of Pediatric T-ALL with Unedited Allogeneic Anti-CD5 CAR-T Cells Manufactured at the Point of Care in Combination with Allo-HSCT	19:55 - 19:55
Elvira Musaeva (Moscow, Russian Federation)	
A multicentre Analysis of CAR-T Cell Toxicities, Target Antigens and Dosing in Solid and Haematological Malignancies	19:55 - 19:55
Neelam Singh (Mumbai, India)	
Estimating the Real Price of CAR T-cells in France: From List Price to Net Price	19:55 - 19:55
Christian Chabannon (Marseille, France)	
Redirected Killing of Allergen-specific CD4⁺ T Cells by pHLA Class II CAR NK-92 Cells	19:55 - 19:55
Isidora Protic Rosic (Vienna, Austria)	
Structure-guided Tuning of a Trastuzumab-based Chimeric Antigen Receptor Enables Tumor-Selective Targeting with Improved Safety and Preserved Efficacy for HER2-positive Breast Cancer	19:55 - 19:55
Maria Lysandrou (Groningen, Netherlands)	
An Indigenous CAR-T Journey: Managing IEC-HS and Tracking Response Using a Homegrown CTDNA Assay	19:55 - 19:55
Anusha Swaminathan (Gurugram, India)	
JOIN4ATMP: Mapping the European Clinical Trial Landscape of Advanced Therapy Medicinal Products (ATMPs)	19:55 - 19:55
Stephanie Winter (Vienna, Austria)	
Prognostic Utility of PET Imaging Parameters in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Undergoing CAR-T Cell Immunotherapy: A Retrospective Single-center Analysis	19:55 - 19:55
Livia Donzelli (Rome, Italy)	
Searching for the Ideal CAR-T Target in AML: Balancing Expression and Toxicity	19:55 - 19:55
Florian Van Oers (Wilrijk, Belgium)	
Eosinophilia as a Novel Biomarker of Toxicity and Response in LBCL Patients Treated with CD19 CAR T-cell Therapy	19:55 - 19:55
Sophia Stock (Munich, Germany)	
Early Experience with T-cell Receptor Cellular Therapy in Advanced Solid Malignancies: A Multi-centre Analysis of Safety and Efficacy	19:55 - 19:55
Neelam Singh (Mumbai, India)	
Developing B7H3-STAR-T Cells to Increase Antigen Sensitivity and Circumvent Tumor Escape by Antigen Downregulation	19:55 - 19:55
Erik Boelter (Berlin, Germany)	
Optimisation of CAR-T Therapy Treatment in Ambulatory Care: Is it Feasible?	19:55 - 19:55
Candan Coban (London, United Kingdom)	

Systemic Barriers to CAR-T Access: Insights from a Certified German Center - First Results from the EASYGEN Consortium	19:55 - 19:55
Dominik Narres (Bad Homburg, Germany)	
Early Follow-up of the First Czech Real-world Data Analysis of Brexucabtagene Autoleucl in the Treatment of Acute Lymphoblastic Leukemia	19:55 - 19:55
Frantisek Folber (Brno, Czech Republic)	
Varnimcabtagene Autoleucl (ARI-0001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Retrospective Study	19:55 - 19:55
Nil Albiol (Barcelona, Spain)	
Adjuvant-backpacked CAR T Cells: CAR-T Cells Equipped with Poly I:C-nanoparticles to Reprogram M2c Immunosuppressive Macrophages and Remodel the Tumor Microenvironment	19:55 - 19:55
Jorge García-Balduz (Ghent, Belgium)	
Exploiting Microbiota to Improve CARCIK Cell Fitness and Metabolism for the Treatment of Acute Myeloid Leukemia	19:55 - 19:55
Orsola Montini (Monza, Italy)	
Interprofessional Simulation-based Training to Enhance Toxicity Recognition and Management during CAR T-cell Service Implementation in Ireland	19:55 - 19:55
Deirdre Moloney (Galway, Ireland)	
Transverse Myelitis as a Rare Non-ICANS Neurotoxicity Following CAR T-Cell Therapy	19:55 - 19:55
Rita Costa e Sousa (Coimbra, Portugal)	
Clinical Experience in Sleeping Beauty Transposon-based CAR-T-Cell Manufacturing	19:55 - 19:55
Sabrina Rebecca Friedel (Würzburg, Germany)	
Optimizing Tocilizumab Dosing in CAR-T-associated Cytokine Release Syndrome: When Less Is Enough	19:55 - 19:55
Jorne Migchelbrink (Amsterdam, Netherlands)	
Reprogramming the Tumor Microenvironment: A CAR-T and CAR-macrophage Dual Approach for Solid Cancers	19:55 - 19:55
Liz Therese Tony (Würzburg, Germany)	
Combining CAR-modified Immune Cells to Overcome Cancer Resistance in Solid Tumors	19:55 - 19:55
Francisca Silva Ferreira (Würzburg, Germany)	
Co-expressing a Conventional and an Adapter CAR Allows for Multi-antigen Targeting in Heterogeneous Multiple Myeloma	19:55 - 19:55
Lea Hammer (Würzburg, Germany)	
Modeling of Metastatic Neuroblastoma in Syngeneic Immunocompetent Mice to Guide Engineering of CAR T Cells	19:55 - 19:55
Efrosiniia Talalai (Berlin, Germany)	
Generation of a Dual-fluorescent NK-cell Reporter System to Monitor CAR-NK Activation and Inhibition	19:55 - 19:55
Dúnia Bobet Cañadell (Würzburg, Germany)	
High-resolution Longitudinal Immune Cell Profiling Reveals Distinct Cellular Patterns Linked to Prolonged Cytopenia after CAR T-cell Therapy	19:55 - 19:55
Julian Liebaert (Berlin, Germany)	
Cesnicabtagene Autoleucl (ARI0002H) in Patients with Ultra-high	19:55 - 19:55

Risk Multiple Myeloma	
Carlos Jimenez-Mira (Barcelona, Spain)	
Acute Kidney Injury in Patients with Multiple Myeloma Receiving Cesnicabtagene Autoleucl (ARI0002h)	19:55 - 19:55
Carlos Jimenez-Mira (Barcelona, Spain)	
In Splenectomized Patients with B-cell Malignancies, CAR-T Cell Therapy Is Well-tolerated and Associated with Low Incidence of Severe Infections	19:55 - 19:55
Ofrat Beyar-Katz (Haifa, Israel)	
GXMR-CAR T Cell Activation Enhanced by Costimulatory Domain in Response to <i>Cryptococcus</i> spp	19:55 - 19:55
Milena Barrocali Araújo MELO (Araraquara, Brazil)	
Targeting CDCP1 with Single-domain Antibody-based CAR T Cells to Treat Solid Tumors	19:55 - 19:55
Franziska Schneppenheim (Bonn, Germany)	
ST2 as a Biomarker of Cytokine Release Syndrome Following CD19-targeted Chimeric Antigen Receptor T-cell Therapy	19:55 - 19:55
Cecilia Carpio (Barcelona, Spain)	
CAR-FIT: CAR-T Fitness Index — Integrating Comorbidity and Geriatric Assessments to Guide Safe and Equitable Delivery of CAR-T in Patients with Borderline Physiological Reserve	19:55 - 19:55
Nicole-Ann Lim (Singapore, Singapore)	
The Cost Savings Potentials of Virtual Twins for Personalised CAR T-cell Therapy in Multiple Myeloma	19:55 - 19:55
Marija Radic (Leipzig, Germany)	
Development of Nectin-2 Specific Nano-CARs for the Treatment of Melanoma	19:55 - 19:55
Carolin Birr (Bonn, Germany)	
Global Brexucabtagene Autoleucl (Brexu-cel) Manufacturing Experience for Adult Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) or Mantle Cell Lymphoma (MCL)	19:55 - 19:55
Clare Spooner (Santa Monica, California, United States)	
iMMagine-3: Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucl with Standard of Care in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	19:55 - 19:55
Clare Spooner (Santa Monica, California, United States)	
Exploring Bone-marrow TILs as an Alternative T-cell Source for CAR-T Therapy in AML	19:55 - 19:55
Zoi Katana (Antwerp, Belgium)	
Immune Cell Profiling in Lymphoma Patients Treated with CAR-T Cell Therapy and Nivolumab	19:55 - 19:55
Anwar Khatib (Kabul, Israel)	
CD37 Is a Promising Molecular Target for CAR-T Cells in Chronic Lymphocytic Leukemia	19:55 - 19:55
Joanna Barankiewicz (Warsaw, Poland)	
Late Parvovirus B19 Reactivation Causing Severe Cytopenias after CD19-directed CAR-T Therapy for Diffuse Large B-cell Lymphoma: A Case Report	19:55 - 19:55
Joanna Barankiewicz (Warsaw, Poland)	
Reinforcing Anti-BCMA CAR T-cells in t(11;14) Multiple Myeloma	19:55 - 19:55

Sarah Vera-Cruz (Würzburg, Germany)

CD4⁺/CD8⁺ CAR⁺ T-cell Ratio at Peak Expansion Predicts Clinical Outcomes Following CAR-T Cell Therapy 19:55 - 19:55

Virginia Quaresima (Brescia, Italy)

Chronic Exposure to CAR-T Secretome Depletes Human Hematopoietic Stem Cells via TNF α /IFN γ -BATF2 Signaling Axis, Reversible by cAMP Pathway Activation 19:55 - 19:55

Siva Sai Naga Anurag Muddineni (Tel Aviv, Israel)

Oral Health of Lymphoma Patients Treated with Car-T Cells 19:55 - 19:55

Boris Aurer (Zagreb, Croatia)

The Experiences of Adult Cancer Patients Receiving Chimeric Antigen Receptor T-cell (CAR-T) Therapy: A Scoping Review 19:55 - 19:55

Isabela Girleanu (Dublin, Ireland)

Novel MHC Multimer Technology for Sensitive Discovery, Analysis, and Enrichment of Antigen-specific T Cells to Advance TCR-based Cancer Immunotherapies 19:55 - 19:55

Nicholas Tokarew (Bergisch Gladbach, Germany)

Functional Properties of CD4⁺ and CD8⁺ CAR T Cells: Can Extreme CD4/CD8 Ratios Impact Release Testing? 19:55 - 19:55

Nicholas Tokarew (Bergisch Gladbach, Germany)

Endogenous T Cell Reprogramming in CAR T Cell Therapy-associated Toxicities in B Cell Lymphoma Patients 19:55 - 19:55

Stefanie Kreutmair (Zurich, Switzerland)

Impact of CAR-T Cell Product Characteristics and Persistence on Clinical Outcomes of Allogeneic Cocktail CD19 and CD22 CAR-T Therapy Following PtCy-based allo-HSCT in Pediatric ALL 19:55 - 19:55

Ekaterina Malakhova (Moscow, Russian Federation)

Artificial Targets for Functional Characterization of CAR T Cells 19:55 - 19:55

Nadine Borgelt (Bergisch Gladbach, Germany)

Monitoring and Clearance of Circulating Plasma Cells (CPCs) in Myeloma Patients Undergoing CAR-T Therapy 19:55 - 19:55

Ilaria Vigliotta (Bologna, Italy)

Impact of Chimeric Antigen Receptor (CAR) Product Cell Phenotypes on Clinical Outcomes Following Treatment with Obecabtagene Autoleucel (Obe-cel) 19:55 - 19:55

Benjamin S Simpson (London, United Kingdom)

CD19 Antigen: From Tumor Target to Safety Switch Able to Improve the Safety Profile of CAR T Cell Therapy 19:55 - 19:55

Simona Manni (Roma, Italy)

Long-term Neurological and Psychiatric Outcomes after CD19 and BCMA Chimeric Antigen Receptor T-cell (CAR-T) Therapy: A Retrospective Analysis of Real-world Data from over 2200 Patients 19:55 - 19:55

Katharine Lynch-Kelly (London, United Kingdom)

Risk Factors to Determinate Tisagenlecleucel Treatment Efficacy in Patients with NHL - Single Center Experience 19:55 - 19:55

Barbara Dreta (Zagreb, Croatia)

Histopathological Predictors of Outcome in CD19 CAR-T Therapy for Diffuse Large B-cell Lymphoma: A National Real-world Cohort Study 19:55 - 19:55

Robert Power (Dublin, Ireland)

CAR-T Timing Matters: Better Immune Fitness with Second-line Axicabtagene Ciloleucel in Relapsed/Refractory Large B-cell Lymphomas	19:55 - 19:55
Cristiana Carniti (Milano, Italy)	
CAR T-cell Therapy in Austria 2024: Demand and Access Challenges	19:55 - 19:55
Sophia Oesterreicher (Vienna, Austria)	
Smoking and Coronary Artery Calcification as Predictors of ICANS in Anti-CD19 CAR T-Cell Therapy for the Treatment of Patients with LBCL	19:55 - 19:55
Tatum N. Storck (Groningen, Netherlands)	
A Spheroid Model to Cultivate Multiple Myeloma Cells in a Stromal/Collagen-based 3D Scaffold and Assess Anti-BCMA CAR-T Cells Activity	19:55 - 19:55
Théo Oliveira (São Paulo, Brazil)	
Real-world Outcomes of Adult Patients with Triple-class Exposed Relapsed or Refractory Multiple Myeloma: Evidence from a Multicenter Retrospective Study (MMIRROR-1)	19:55 - 19:55
Taha Itani (Santa Monica, United States)	
Real-world Data of CAR T Therapy in Large B-cell Lymphoma - Outcomes from the First 100 Patients Treated in Ireland	19:55 - 19:55
Robert Power (Dublin, Ireland)	
Timing of G-CSF Use during Cytokine Release Syndrome Following CD19 CAR T-cell Therapy in Refractory Ph-like B-ALL: A Clinical Learning Experience	19:55 - 19:55
Rationale for the T2EVOLVE Pilot Project to Use a New Patient-centred Format for the Informed Consent Form in a German Multicentre Phase-I CAR T-cell Study	19:55 - 19:55
Barbara Huber (Würzburg, Germany)	
Severe Case of ICANS in Patient with Classic Follicular Lymphoma Treated with Tisagenlecleucel after Bridging Therapy with Mosunetuzumab	19:55 - 19:55
Neno Živković (Zagreb, Croatia)	
ApoE-DARPin Fusion Proteins Enable Cell-specific mRNA Delivery by Lipid Nanoparticles	19:55 - 19:55
Elham Adabi (Langen, Germany)	
A Protein Engineering Strategy to Generate Novel Anti-CD72 Ligands for a CAR-T Approach to Pediatric AML and B-ALL	19:55 - 19:55
Silvia Merlini (Padova, Italy)	
Efficient and Rapid Generation of CAR-T Cells in GMP-scalable Devices	19:55 - 19:55
Sara Boscarato (Padova, Italy)	
Etoposide as an Effective Rescue Treatment for Severe IEC-HS after CAR-T Cell Treatment for Progressive Multiple Myeloma	19:55 - 19:55
Theresa Schlemmer (Hamburg, Germany)	
B7-H3-Directed CAR T Cells as a Promising Therapeutic Strategy for Acute Myeloid Leukemia	19:55 - 19:55
Pamela De Falco (Rome, Italy)	
Respiratory Complications in CAR T-cell Therapy Recipients: Insights from a Single UK Centre	19:55 - 19:55
A New Deep Learning Model for the Automatic Recognition of Lymphocyte Differential during the Hematopoietic Recovery after	19:55 - 19:55

CAR-T Therapy

José Rodellar (Barcelona, Spain)

Understanding the Mechanistic Role of the Intestinal Microbiome on CAR T Cell Therapy Outcomes in a Preclinical Mouse Model 19:55 - 19:55

Charlotte Subklewe (Heidelberg, Germany)

Peptide-mediated Delivery of Gene-editing Tools for Efficient Engineering of Primary Human T Cells 19:55 - 19:55

Aysenur Öner (Groningen, Netherlands)

Engineering Caffeine-responsive Molecular Switches to Control CAR T Cell Function *in vivo* 19:55 - 19:55

Michael W. Traxlmayr (Vienna, Austria)

Application of the CAR-hematotox Score in Patients Undergoing Anti-CD19 CAR-T Cell Therapy at the University Hospital Complex of A Coruña 19:55 - 19:55

Tamara Torrado Chedas (A Coruña, Spain)

Impact of Polatuzumab Vedotin as Bridging Therapy in Relapsed or Refractory Aggressive B-cell Lymphomas: Single-center Experience with Axicabtagene Ciloleucel (Yescarta®) 19:55 - 19:55

Concepción Sánchez Chamizo (Las Palmas de Gran Canaria, Spain)

Impact of Prior Antibiotic Exposure on the Outcomes of Bispecific Antibodies in Non-Hodgkin B-cell Lymphomas: A Real-world Retrospective Study 19:55 - 19:55

Ana Cuervo Fonseca (Madrid, Spain)

Engineering and Optimization of Non-viral Nanocarriers for CAR-T Cell Manufacturing 19:55 - 19:55

Alberto Jimenez Lomo (Santiago de Compostela, Spain)

Co-designed CAR T-cell Therapy Education: Launching a CPD Certified E-learning Resource for Healthcare Professionals 19:55 - 19:55

Emily John (London, United Kingdom)

Unmasking Mechanisms of TME-driven CAR-T Cell Dysfunction in Solid Tumors 19:55 - 19:55

Juan Roberto Rodriguez-Madoz (Pamplona, Spain)

Uncovering Key Regulators of CAR-T Cell Senescence via Integrated CRISPR Screens and Immune Phenotyping 19:55 - 19:55

Juan Roberto Rodriguez-Madoz (Pamplona, Spain)

Molecular Characterization of Extraordinary Long-persistent CAR-T Cells in a R/R MM Patient Treated with Academic BCMA-targeting CAR-T Therapy 19:55 - 19:55

Juan Roberto Rodriguez-Madoz (Pamplona, Spain)

Novel HER2-specific sdAb-based CAR-T Cells Exhibit Enhanced Antitumoral Efficacy in HER2-positive Cancers 19:55 - 19:55

Juan Roberto Rodriguez-Madoz (Pamplona, Spain)

Establishing a Nurse-led Solid Tumour Cell Therapy Clinic for Patients on Clinical Trials Including a Preliminary Evaluation 19:55 - 19:55

Maia Collins (London, United Kingdom)

Place-of-Care Produced Fresh Formulation CD19 CAR-T Cell Therapy in Patients with Relapsed or Refractory CD19+ B-cell Acute Lymphocytic Leukemia 19:55 - 19:55

Ruta Semaskeviciene (Vilnius, Lithuania)

Time of Infusion Does Not Significantly Impact Outcomes Following CAR T-cell Therapy in Large B-cell Lymphoma 19:55 - 19:55

Edward Cliff (Melbourne, Australia)	
Novel Salinomycin Analogs Potentiate Anti-CD20 CAR-T and Antibody-dependent Immunotherapy	19:55 - 19:55
Bhaskar Pradhan (Warsaw, Poland)	
Lactobacillus-derived Postbiotics Enhance CAR T Cells Cytotoxicity and <i>in vivo</i> Tumor Control	19:55 - 19:55
Kai Ziegler-Martin (Würzburg, Germany)	
Durability of Tisagenlecleucel in Pediatric ALL Is Associated with Post Allo-HSCT Status	19:55 - 19:55
Rakefet Sidlik Muskatel (Petach Tikva, Israel)	
CAR T-cells Dysfunction in the Central Nervous System Is Mediated by BBB-induced AICD	19:55 - 19:55
Yarden Aharony Tevet (Ramat Gan, Israel)	
Shortened Half-life "FadeAway"-Sleeping Beauty Transposase for Production of Enhanced Biosafety CAR T-cells	19:55 - 19:55
Dominik Andrae (Würzburg, Germany)	
Preclinical Evaluation of Novel Target Modules for Adoptive UniCAR T Cell Therapy Targeting Solid Tumors	19:55 - 19:55
Justyna Jureczek (Heidelberg, Germany)	
Detectable CAR T-cells Seven Years Post-infusion in a Patient with Sustained Remission of Diffuse Large B-cell Lymphoma	19:55 - 19:55
Monique C. Minnema (Utrecht, Netherlands)	
Pharmacological Modulation with PI3K and CBP/P300 Inhibition Enhances <i>ex vivo</i> Expansion and Enrichment of CAR30 Memory Stem T Cells	19:55 - 19:55
Irene Pascual-Latorre (Barcelona, Spain)	
Evaluation of T Cells Derived from Bare Lymphocyte Syndrome Type I Donors as a Novel Source for Universal CAR-T Manufacturing	19:55 - 19:55
Towards Scalable Production of Virus-specific CAR T Cells Using Cryopreserved Donor T-cell Banks	19:55 - 19:55
Ane Altuna (Barcelona, Spain)	
Hospital Exemption for 3rd Generation CD19.CAR T Cell Therapy in Germany	19:55 - 19:55
Michael Schmitt (Heidelberg, Germany)	
Non-compliant Manufacturing of Commercial Autologous CAR T-cells Could Be Associated with High Neutrophils or Low Platelets Concentrations in the Apheresis Product	19:55 - 19:55
Cécile WERTHE (Paris, France)	
Exploring T-cell Therapies: Understanding the Distinct Mechanisms and Uses of CAR-T and TCR-T Cells	19:55 - 19:55
Anna Andrzejczak (Wrocław, Poland)	
Pulmonary Function Tests Performed prior to CAR-T Cell Administration Could Be Instrumental in Predicting Post-treatment Pulmonary Toxicity: A Single-arm Prospective Study	19:55 - 19:55
Ofrat Beyar-Katz (Haifa, Israel)	
Distinct Cellular Signatures in Aplastic and Intermittent Phenotypes of Immune Effector Cell-associated Hematotoxicity	19:55 - 19:55
Ofrat Beyar-Katz (Haifa, Israel)	
Bridging Oncology and Autoimmunity: The New Challenge for	19:55 - 19:55

Oncology Nursing Care in Pediatric Lupus Erythematosus Patients Undergoing CAR-T Cell Therapy	
Matteo Amicucci (Roma, Italy)	
The Rationale behind Targeting Minimal Residual Disease in Pancreatic Ductal Adenocarcinoma with Allogeneic CAR-T Therapy	19:55 - 19:55
Marcin Piejko (Krakow, Poland)	
Evaluating the Impact of Frailty on Clinical Outcomes in Older Adults Undergoing CAR-T Cell Therapy: A Real-world Study	19:55 - 19:55
Olivia Lamb (Bristol, United Kingdom)	
Rapcabtagene Autoleucel (YTB323) in Adult Patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL): Phase 1 Evaluation of the Safety and Efficacy	19:55 - 19:55
Pere Barba (Barcelona, Spain)	
CAR-T Cell Therapy as Bridge to Allogeneic Stem Cell Transplantation in a Heavily Pre-treated Follicular Lymphoma Patient	19:55 - 19:55
Enrico Amaducci (Torino, Italy)	
Durable Efficacy Academic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma	19:55 - 19:55
Katsiaryna Zharkova (Minsk, Belarus)	
Turning Blood Counts into Real-time CAR T-cell Immune Monitoring: Leveraging Sysmex-XR Cell Population Data and Digital Morphology for Detection of Immune Activation and Clinical Complications	19:55 - 19:55
Anna Merino (Barcelona, Spain)	
Phase I Evaluation of piggyBac-Engineered CD19 CAR T Cells with an Enhanced Tscm Profile for Refractory B-cell Malignancies	19:55 - 19:55
Martin Štách (Prague, Czech Republic)	
Linear DNA PiggyBac-engineered CD123 CAR-T Cells: Launch of a Phase I AML Trial	19:55 - 19:55
Martin Štách (Prague, Czech Republic)	
Optimizing B7-H3.CAR T-cell Therapy for Medulloblastoma: Preclinical Evidence Supporting CD28.OX40ζ Design	19:55 - 19:55
Maria Cecilia Quadraccia (Rome, Italy)	
A First-in-Class CAR T-Cell Therapy Targeting Mutant Calreticulin in Myeloproliferative Syndromes: Preclinical Development and Clinical Trial Design	19:55 - 19:55
Cecilia Pesini (Zaragoza, Spain)	
Combining Sleeping Beauty Transposon with Base Editing Platform for Next-generation Allogeneic CAR-T Cell Therapy	19:55 - 19:55
Adarsh Ajayakumar (Ostrava, Czech Republic)	
CAR-T Therapy without Allogeneic HSCT in Children with Down Syndrome-associated High-risk Pre-B-ALL: A Single-center Series	19:55 - 19:55
Olga Molostova (Moscow, Russian Federation)	
Phase 2 ELARA 5-year Update: Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL)	19:55 - 19:55
Catherine Thieblemont (Paris, France)	
CD19-CD22 Coregulation Shapes Antigen Selection in Multi-target CAR T-cell Strategies for B-cell Malignancies	19:55 - 19:55
Aditya Ramdas Iyer (Delhi, India)	

Harnessing $\gamma\delta$ CAR T-cells to Combat Immune Suppression in Ovarian Cancer	19:55 - 19:55
Paula Hahn (Huddinge, Sweden)	
Evaluating Operator Impact, Process Consistency, and Predictive Modeling in CD3⁺ Cell Collections for CAR-T Manufacturing	19:55 - 19:55
Patricia Jarabo-Blázquez (Madrid, Spain)	
Establishing a Decentralized GMP Manufacturing Model for GYA01, a Novel Anti-CD84 CAR-T Therapy: Design, Validation, and Comparability	19:55 - 19:55
Leticia Alserawan (Barcelona, Spain)	
Complement Activation as a Therapeutic Target for ICANS Following CAR T-cell Therapy	19:55 - 19:55
Aleksandr Lazaryan (Tampa, United States)	
Characteristics and Clinical Impact of Oligoclonal Band Appearance in Multiple Myeloma Patients Treated with the Academic CAR-T ARI0002H	19:55 - 19:55
Daniel Munárriz (Barcelona, Spain)	
Directing CART Cells against Ligand-activated EGFR	19:55 - 19:55
Delia Sumesgutner (Vienna, Austria)	
miniCARbids - A Novel and Versatile Platform for Engineering of Minimalistic Human-derived CAR Binding Domains	19:55 - 19:55
Julia Mayer (Vienna, Austria)	
Current Practices, Organizational Structures, Technologies and Challenges in Developing ATMPs: A Survey by DARE-NL, NXTGEN Hightech, T2EVOLVE and EBMT - A GoCART Coalition Initiative	19:55 - 19:55
Anil Kumar Deshantri (Utrecht, Netherlands)	
Modeling Immune Escape and Antigen-loss-Driven Resistance to CAR T-cell Therapy in Medulloblastoma with Innovative in vivo & ex vivo Approaches	19:55 - 19:55
Marvin Müller (Freiburg, Germany)	
Metabolic Fitness of the Final ARI0002h CAR-T Product Predicts Treatment Outcome in Multiple Myeloma	19:55 - 19:55
Joan Mañé Pujol (Barcelona, Spain)	
Neurolymphomatosis Mimicking Guillain-Barré Syndrome and Fungal Infection Following Car-T Cell Therapy: A Case Report	19:55 - 19:55
Mercè Arén-Jubany (Badalona, Spain)	
Serum HLC Analysis as a Practical Tool for Response and Immune Monitoring after ARI0002h AntiBCMA CAR-T Therapy	19:55 - 19:55
Anna de Daniel (Barcelona, Spain)	
From Adults to Pediatrics: Procedural Insights into PBMC Collections for CAR T Therapies Using Spectra Optia	19:55 - 19:55
Patricia Jarabo-Blázquez (Madrid, Spain)	
Systematic Discovery of CRISPR-boosted CAR T Cell Immunotherapies	19:55 - 19:55
Cosmas D. Arnold (Vienna, Austria)	
Hemophagocytosis-like Syndrome and Refractory Cytopenias in Two Patients with DLBCL Post-CAR-T Therapy	19:55 - 19:55
Miriam Sanchez Escamilla (Santander, Spain)	
Optimizing Quality of Life and Reducing Financial Toxicity in CAR-T Therapy: A Prospective Cohort from a Referral Center	19:55 - 19:55
Mercedes Montoro-Lorite (Barcelona, Spain)	

Personalised Multilevel Modelling to Unveil Mechanisms behind Engineered T Cell Therapy Response in Multiple Myeloma	19:55 - 19:55
Frida Sophia Orozco-Ruiz (Paris, France)	
Impact of Dasatinib Supplementation on GMP-Grade CAR-T Cell Production	19:55 - 19:55
Marta Español-Rego (Barcelona, Spain)	
A New 41-colour Spectral Flow Panel for the In-depth Characterisation Potential Immunoregulatory Cells in Whole Blood in the Context of CAR-T Cell Therapy	19:55 - 19:55
Lena Elke Rockstein (Groningen, Netherlands)	
Dual-targeting CAR T-cells Overcome <i>in vivo</i> Escape Strategies and Clear Primary Pediatric AML in PDX Models	19:55 - 19:55
Maren Soldierer (Essen, Germany)	
ROADSTAR Platform Enables CAR-adapted PIK3CD Base-editing Screens to Enhance CAR T Cell Anti-tumor Activity	19:55 - 19:55
Philip Bucher (Tübingen, Germany)	
Automated Manufacturing of GD2-IL18 CAR T Cells for the Treatment of Glioblastoma Multiforme Using the CliniMACS Prodigy® Platform	19:55 - 19:55
Sandy Reiß (Bergisch Gladbach, Germany)	
A Versatile Non-viral Platform for ex vivo and in vivo T Cell Engineering	19:55 - 19:55
Lucía Sanjurjo (Santiago de Compostela, Spain)	
Effectiveness of Bridging Therapy Corresponds to Improved Outcomes after Ciltacabtagene Autoleucel: Phase 3 CARTITUDE-4 Study of Patients with Relapsed, Lenalidomide-refractory Multiple Myeloma	19:55 - 19:55
Paula Rodríguez-Otero (Pamplona, Spain)	
Acquisition of an Immunosuppressive Microenvironment after CAR-T Therapy Drives T-cell Dysfunction and Resistance	19:55 - 19:55
Two-step Multiparameter Screen Identifies NFIL3 as Driver of CAR T Cell Dysfunction	19:55 - 19:55
Celina May (Tübingen, Germany)	
Ciltacabtagene Autoleucel Out-of-Specification Manufacturing Outcomes Improve with Earlier Lines of Therapy	19:55 - 19:55
Robert Bowden (Spring House, United States)	
Antigen-scaffolds Drive Preferential Expansion of Functional Genetically Engineered CAR and TCR T Cells	19:55 - 19:55
Keerthana Ramanathan (Kgs. Lyngby, Copenhagen, Denmark)	
Cytokine-driven Modulation of CART84 Phenotype and Function for AML Therapy	19:55 - 19:55
Ane Altuna (Barcelona, Spain)	
Localized Cytokine Release Syndrome Presenting as Cervical Angioedema: An Unusual Complication of CAR-T Cell Therapy	19:55 - 19:55
Karney Lahad (Haifa, Israel)	
CERTOMICS: Trusted Single-cell Multiomics Pipeline for High-resolution Profiling of Adoptive Cellular Immunotherapies	19:55 - 19:55
Christina Kuhn (Leipzig, Germany)	
A Novel Severe Toxicity-free and Progression-free Survival Endpoint after CD19 Chimeric Antigen Receptor T Cell Therapy in Mantle Cell Lymphoma	19:55 - 19:55

Aleksandr Lazaryan (Tampa, United States)	
Targeted Therapies as Bridging in Mantle Cell Lymphoma Patients Treated with Commercial Anti-CD19 CAR T Cell Therapies: Real-world Experience from a UK Centre	19:55 - 19:55
Stella Bouziana (London, United Kingdom)	
Management of ICANS after CAR-T Therapy: Treatment Patterns and Outcomes in a Real-world Cohort from Six German Centers	19:55 - 19:55
Veit Bücklein (Munich, Germany)	
Intraventricular CD19 CAR-T Therapy for Relapsed Primary CNS Lymphoma: Case Series of Two Patients	19:55 - 19:55
Andrei Chyzh (Minsk, Belarus)	
First Results of Academic Anti-CD19 CAR-T Therapy in Russia for Adult Patients with Refractory/Relapsed B-cell Acute Lymphoblastic Leukemia	19:55 - 19:55
Olga Aleshina (Moscow, Russian Federation)	
Overcoming Tumor Apoptosis Resistance by Enhancing Chimeric Antigen Receptor T-cell Cytotoxicity by Delivery of Cathepsins through the Granzyme-perforin Pathway	19:55 - 19:55
Mikkel Rasmus Hansen (Odense M, Denmark)	
Systematic Discovery of CRISPR-boosted CAR T Cell Immunotherapies	19:55 - 19:55
Cosmas D. Arnold (Vienna, Austria)	
Repeated Infusion of Brexucabtagene Autoleucel in a Mantle Cell Lymphoma Patient with Secondary CNS Involvement	19:55 - 19:55
Markus Maulhardt (Göttingen, Germany)	
When CAR-T Becomes the Enemy: Case Report of a Child with Late Progressive Necrotic Leukoencephalopathy Following CD 19 CAR-T for CNS Relapse with ALL	19:55 - 19:55
Marta Rojas (Edmonton, Canada)	
In vivo monitoring of CAR-T cell therapy: the role of multiparametric flow cytometry in lymphocyte expansion analysis	19:55 - 19:55
Renato Scalone (Palermo, Italy)	
Pharmacist Medication Review for Patients Preparing for Chimeric Antigen Receptor T-cell Therapy - A Service Evaluation	19:55 - 19:55
Madeleine Norbury (Southampton, United Kingdom)	
A Multicenter Trial of Varnimcabtagene Autoleucel (VAR-CEL) For Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (CART19-BE-02 Trial)	19:55 - 19:55
Valentín Ortiz-Maldonado (Barcelona, Spain)	
Patient-Reported Outcomes of CAR T-cell Therapy: Update on A European Study Evaluating Patients' Experiences, Quality of Life and Unmet Care Needs	19:55 - 19:55
Elise Pennings (Netherlands)	

Friday, February 13, 2026

Best Abstracts

08:30 - 09:30

Plenary

BA1 - Best Abstracts 1

Michael Hudecek (Würzburg, Germany)

Valentín Ortiz-Maldonado (Barcelona, Spain)

BA1-1 **Disrupting miR-146a-mediated Suppression Restores CAR T-cell Functionality** 08:30 - 08:40

Anna-Sophia Baur (Freiburg, Germany)

BA1-3 **Implications of Costimulatory Domain Choice: 4-1BB-CAR-T Cells Promote CD19 Mutation-associated Resistance in Hematologic Malignancies** 08:40 - 08:50

Marta Krawczyk (Warsaw, Poland)

BA1-4 **Decreased Hematologic Toxicity and Infectious Complications in LBCL Patients Receiving CD19 CAR-T in Earlier versus Advanced Treatment Lines** 08:50 - 09:00

Linus Kruk (Munich, Germany)

BA1-5 **A Novel CAR-T Cell Therapy Product (Talicabtagene Autoleucel: Tali-cel) Shows Promising Activity in Relapsed/ Refractory B-acute Lymphoblastic-leukemia (R/R B-ALL) Patients: Phase Ib/II Clinical Trial** 09:00 - 09:10

Gaurav Narula (Mumbai, India)

BA1-6 **Boosting CAR T-cell Therapy in Multiple Myeloma Combining *in silico* Perturbation Predictions and Drug Repurposing** 09:10 - 09:20

Alessia Buratin (Barcelona, Spain)

Physicians Session

08:30 - 09:30

Breakout

PS4 - Clinical Cases & Keynote Lecture (Katy Rezvani)

Alexandros Rampotas (London, United Kingdom)

Koray Yalcin (İstanbul, Turkey)

Stephan Mielke (Stockholm, Sweden)

PS4-1 **Myeloma clinical case** 08:30 - 08:50

Hermann Einsele (Würzburg, Germany)

PS4-3 **Complete Response in Relapsed/Refractory POEMS Syndrome after ARI0002h, an Academic BCMA-directed CAR-T Cell Therapy: A Case Report** 08:50 - 09:00

Víctor Torrecillas (Barcelona, Spain)

PS4-4 **Keynote lecture: NK** 09:00 - 09:30

Katy Rezvani (Houston, United States)

Nurses Session

08:30 - 09:15

Menorca

NG1 - Opening and Keynote Lecture on CAR T beyond haematological disorders

Hilda Mekelenkamp (Leiden, Netherlands)

Mairéad NíChonghaile (Dublin, Ireland)

NG1-1 **Welcome and Introduction** 08:30 - 08:40

Hilda Mekelenkamp (Leiden, Netherlands)

Mairéad NíChonghaile (Dublin, Ireland)

NG1-2 **CAR T beyond haematological disorders** 08:40 - 09:15

Raffaella Greco (Milano, Italy)

Nurses Session

09:30 - 10:45

Menorca

NG2 - Exploring CAR T cell Therapy

Erik Aerts (Zürich, Switzerland)

Ruth Clout (Manchester, United Kingdom)

NG2-4	Bridging Therapy and implications in CAR T Erik Aerts (Zürich, Switzerland)	09:30 - 09:50
NG2-3	Symptom Management Ruth Clout (Manchester, United Kingdom)	09:50 - 10:10
NG2-2	Models of care for CAR T programmes Emily John (London, United Kingdom)	10:10 - 10:30
NG2-1	The role of CAR T in Myeloma Monique C. Minnema (Utrecht, Netherlands)	10:30 - 10:45

Physicians Session

09:45 - 10:45

Plenary

PS5A - Solid tumours

Concetta Quintarelli (Rome, Italy)

Annette Künkele (Berlin, Germany)

PS5A-1	Beyond hematology: CART for pediatric solid tumors Francesca del Bufalo (Rome, Italy)	09:45 - 10:05
PS5A-2	NAP CAR T cells for solid tumors Magnus Essand (Uppsala, Sweden)	10:05 - 10:25
PS5A-3	GPC3 CAR-T cells for patients with solid cancers David H. Steffin (Houston, United States)	10:25 - 10:45

Physicians Session

09:45 - 10:45

Breakout

PS5B - International Session

Raffaella Greco (Milano, Italy)

Vanderson Rocha (São Paulo, Brazil)

PS5B-1	Greece Alexandros Spyridonidis (Patras, Greece)	09:45 - 10:05
PS5B-2	Brazil Vanderson Rocha (São Paulo, Brazil)	10:05 - 10:25
PS5B-3	Russia Michael Maschan (Moscow, Russian Federation)	10:25 - 10:45

Break

10:45 - 11:25

IT

Coffee Break*Best Abstracts*

11:00 - 11:10

IT

EIA01 - Update on 5th Emerging Investigators EBMT-EHA Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy

A Multicenter Trial of Varnimcabtogene Autoleucel (VAR-CEL) For Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (CART19-BE-02 Trial)

Valentín Ortiz-Maldonado (Barcelona, Spain)

11:00 - 11:10

Physicians Session

11:25 - 12:55

Plenary

PS6A - Indications beyond cancer

Raffaella Greco (Milano, Italy)

Ibrahim Yakoub-Agha (Lille, France)

PS6A-1	Profiling patients at risk for CART complications Fabio Ciceri (Milano, Italy)	11:25 - 11:45
PS6A-2	CART in rheumatic autoimmune diseases Dimitrios Mougiakakos (Magdeburg, Germany)	11:45 - 12:05
PS6A-3	Haemophilia Felicitas Thol (Hannover, Germany)	12:05 - 12:25

Physicians Session

11:25 - 12:55

Breakout

PS6B - Manufacturing & Regulatory aspects

Ulrike Köhl (Leipzig, Germany)

Christian Chabannon (Marseille, France)

PS6B-1	The complicated patent landscape of T cell based therapies Ulrich Storz (Duesseldorf, Germany)	11:25 - 11:42
PS6B-2	Evidence generation for regulatory decision-making Lourens Bloem (Utrecht, Netherlands)	11:42 - 11:59
PS6B-4	Switching from viral to non-viral gene transfer for CAR manufacturing Ulrike Köhl (Leipzig, Germany)	11:59 - 12:16
PS6B-5	Allo CAR T manufacturing Waseem Qasim (London, United Kingdom)	12:16 - 12:33
PS6B-6	Discussion	12:33 - 12:55

Nurses Session

11:25 - 13:00

Menorca

NG3 - Navigating social and care challenges in CAR T Therapy

Michelle Kenyon (London, United Kingdom)

Sara Ubovic (Zürich, Switzerland)

NG3-1	The challenges of CAR T in adolescents & young adults Matteo Amicucci (Roma, Italy)	11:25 - 11:50
NG3-2	Social media - a bonus to CAR T therapy - advantages & challenges Thomas Jezequel (Nantes, France)	11:50 - 12:10
NG3-3	Advanced Care Planning and CAR T therapy Joica Benschop (Rotterdam, Netherlands)	12:10 - 12:35
NG3-4	Advanced Practice Roles in CAR T, opportunities, challenges & future directions Daniel Kisielewski (Stuttgart, Germany)	12:35 - 13:00

Break

12:55 - 13:45

IT

Lunch Break

Satellite Symposium

13:45 - 14:30

Plenary

SS02 - Satellite Symposium by Johnson & Johnson: Redefine the second-line: a case for CAR-T in multiple myeloma

Hermann Einsele (Würzburg, Germany)

SS02-1 **Introduction: the evolution of CAR-T in MM** 13:45 - 13:55

Hermann Einsele (Würzburg, Germany)

SS02-2 **Translation into practice: insights from trials and real-world experiences** 13:55 - 14:15

Paula Rodríguez-Otero (Pamplona, Spain)

Michel Delforge (Leuven, Belgium)

SS02-3 **Voices from the clinic** 14:15 - 14:30

Hermann Einsele (Würzburg, Germany)

Paula Rodríguez-Otero (Pamplona, Spain)

Michel Delforge (Leuven, Belgium)

Nurses Session

13:45 - 14:30

Menorca

NG4 - Best Abstracts

Hilda Mekelenkamp (Leiden, Netherlands)

Mairéad NíChonghaile (Dublin, Ireland)

BANG-1 **Survey on Fertility Management and Outcomes after Cellular Therapies, on behalf of the EBMT Cellular Therapy and Immunobiology Working Party** 13:45 - 13:54

Giorgio Orofino (Milan, Italy)

BANG-2 **Patient-reported Outcomes: Challenges with Cognitive Impairment Post CAR-T Treatment** 13:54 - 14:03

Natacha Bolaños (Madrid, Spain)

BANG-3 **Time from Onset to Severe ICANS Following CAR-T Therapy: A Retrospective Study to Inform ICE Assessment Frequency** 14:03 - 14:12

Jemma Stewart (Melbourne, Australia)

Ella Weisser (Melbourne, Australia)

BANG-4 **Dermatological Complications in CAR-T Cells Therapy: A New Clinical Challenge for BMT Nurses** 14:12 - 14:21

Matteo COSCI (Florence, Italy)

BANG-5 **Combination of Low Physical Performance and Sarcopenia Is Associated with Inferior Outcomes in CAR T-cell Recipients: Results of a Real-world Pilot Study** 14:21 - 14:30

Alessandra Holzem (Munich, Germany)

Physicians Session

14:45 - 16:15

Plenary

PS7 - Translational II: Keynote Lecture (Michel Sadelain) & CAR T models & mechanisms

Michael Hudecek (Würzburg, Germany)

Sonia Guedan (Barcelona, Spain)

PS7-1 **Keynote Lecture** 14:45 - 15:15

Michel Sadelain (New York, United States)

PS7-2 **Multi-omics Single cell, 3D imaging and resistance in niche** 15:15 - 15:35

Zsolt Sebestyen (Utrecht, Netherlands)

PS7-3 **Enhancing CAR T efficacy** 15:35 - 15:55

Evan Weber (Philadelphia, United States)

PS7-4 **Dissection of CAR T cell function in Glioblastoma** 15:55 - 16:15

Cécile Alanio (Paris, France)

Nurses Session

14:45 - 16:15

Menorca

NG5 - Survivorship & Outcomes in CAR T

Hilda Mekelenkamp (Leiden, Netherlands)

Mairéad NíChonghaile (Dublin, Ireland)

NG5-1	Case presentation Mairéad NíChonghaile (Dublin, Ireland)	14:45 - 14:55
NG5-2	Nurses experiences Sara Ubovic (Zürich, Switzerland)	14:55 - 15:10
NG5-3	QoL in patients after CAR T Mercedes Montoro-Lorite (Barcelona, Spain)	15:10 - 15:25
NG5-4	Survivorship, the road to recovery Michelle Kenyon (London, United Kingdom)	15:25 - 15:40
NG5-6	Discussion	15:40 - 16:15

Break

16:15 - 16:50

IT

Coffee Break*Industry Theatre*

16:25 - 16:45

IT

IT03 - Industry Theatre by Bristol Myers Squibb: CAR T Patient Experience: Can QoL be further improved with outpatient care?

Corey Porter (Lawrence, United States)

IT03-01	Improving quality of life for MM patients with CAR T therapy Carlos Fernández De Larrea (Barcelona, Spain)	16:25 - 16:35
IT03-02	Impact and practical considerations for outpatient care Carlos Fernández De Larrea (Barcelona, Spain)	16:35 - 16:43
IT03-03	Summary and Q&A Corey Porter (Lawrence, United States)	16:43 - 16:45

Satellite Symposium

16:50 - 17:35

Plenary

SS03 - Satellite Symposium by Gilead and Kite: Real world, real lives: Navigating the RWE shaping CAR T care in R/R DLBCL

Gloria Iacoboni (Barcelona, Spain)

SS03-01	Welcome and introduction Gloria Iacoboni (Barcelona, Spain)	16:50 - 16:53
SS03-02	Decoding the evidence: An approach to comparing RWE Gloria Iacoboni (Barcelona, Spain)	16:53 - 17:03
SS03-03	Building confidence with evidence: Real-world insights into CAR T management Leyre Bento (Palma de Mallorca, Spain)	17:03 - 17:13
SS03-04	Panel discussion Gloria Iacoboni (Barcelona, Spain) Leyre Bento (Palma de Mallorca, Spain)	17:13 - 17:18
SS03-05	The speed advantage: Exploring how rapid and reliable	17:18 - 17:28

	manufacturing impacts patient care	
	Leyre Bento (Palma de Mallorca, Spain)	
SS03-06	Audience Q&A	17:28 - 17:33
	Gloria Iacoboni (Barcelona, Spain)	
	Leyre Bento (Palma de Mallorca, Spain)	
SS03-07	Conclusion and closing remarks	17:33 - 17:35
	Gloria Iacoboni (Barcelona, Spain)	
<i>Nurses Session</i>		
16:50 - 17:30		Menorca
NG6 - Keynote Lecture on Patient & Stakeholder Engagement- a true collaborative approach to care		
Hilda Mekelenkamp (Leiden, Netherlands)		
Mairéad NíChonghaile (Dublin, Ireland)		
NG6-1	Patient & Stakeholder Engagement- a true collaborative approach to care	16:50 - 17:20
	Natacha Bolaños (Madrid, Spain)	
NG6-2	Discussion	17:20 - 17:30
<i>Nurses Session</i>		
17:30 - 17:45		Menorca
NG7 - Closing remarks		
Mairéad NíChonghaile (Dublin, Ireland)		
Hilda Mekelenkamp (Leiden, Netherlands)		
NG7-1	Closing remarks	17:30 - 17:45
<i>Keynote</i>		
17:45 - 18:15		Plenary
KN3 - Keynote Lecture 3 Marcela Maus		
Ulrike Köhl (Leipzig, Germany)		
KN3	Keynote Lecture	17:45 - 18:15
	Marcela Maus (Boston, United States)	
<i>Keynote</i>		
18:25 - 19:10		Plenary
KN4 - Keynote Roundtable		
Maria Themeli (Amsterdam, Netherlands)		
Annalisa Ruggeri (Milan, Italy)		
	Keynote Roundtable	18:25 - 18:25
	Marcela Maus (Boston, United States)	
	Carl June (Philadelphia, United States)	
	Michel Sadelain (New York, United States)	
	Katy Rezvani (Houston, United States)	
	Dirk Busch (Munich, Germany)	

Saturday, February 14, 2026

Physicians Session

08:30 - 10:00

Plenary

PS9A - Lymphomas and CLL

Stephan Mielke (Stockholm, Sweden)

Anna Sureda (Barcelona, Spain)

PS9A-1	CLL Maria Luisa Schubert (Heidelberg, Germany)	08:30 - 08:50
PS9A-2	Bispecifics vs CART Catherine Thieblemont (Paris, France)	08:50 - 09:10
PS9A-3	NHL Tom van Meerten (Groningen, Netherlands)	09:10 - 09:30
PS9A-4	T-NHL & HL Javier Briones (Barcelona, Spain)	09:30 - 09:50
PS9A-5	Discussion	09:50 - 10:00

Best Abstracts

08:30 - 09:40

Breakout

BA2 - Best abstracts 2

Koray Yalcin (İstanbul, Turkey)

Alexandros Rampotas (London, United Kingdom)

BA2-1	CD19/CD84 IF-BETTER Dual CAR T Cells Overcome Antigen-low Relapse and Outperform CART19 in CD19-low B-ALL Models Ane Altuna (Barcelona, Spain)	08:30 - 08:40
BA2-2	Successful Treatment of Patients with Relapsed/Refractory Systemic Light Chain Amyloidosis with the Novel MDC-CAR-BCMA001 Kiasvasch Mohammad Nejad Farid (Heidelberg, Germany)	08:40 - 08:50
BA2-3	Endothelial Dysfunction and Astrocyte Reactivity Drive ICANS in CAR-T Cell Therapy Rita El Khoury (Milan, Italy)	08:50 - 09:00
BA2-4	Early Intervention for Cytokine Release Syndrome after CAR T-cell Therapy Is Associated with Increased Risk of Cytopenias and Infections in Patients with Large B-cell Lymphoma Gloria Iacoboni (Barcelona, Spain)	09:00 - 09:10
BA2-5	CCL8⁺CCL13⁺ Tumor-associated Macrophages Drive Early Resistance to CAR T-cell Therapy in Large B-cell Lymphoma Anne Marijn Kramer (Palo Alto, United States)	09:10 - 09:20
BA2-6	Cellular Kinetics, Efficacy, and Safety of Zamtocabtagene Autoleucel, a Tandem CD20-CD19 Directed CAR-T Cell Therapy, vs R-GemOx in Patients with Relapsed/Refractory LBCL (DALY 2-EU Study) Gloria Iacoboni (Barcelona, Spain)	09:20 - 09:30
BA2-7	An Open CAR-T Single-cell Atlas to Enable In-depth Characterization and Rational Engineering of CAR-T Products Juan Roberto Rodriguez-Madoz (Pamplona, Spain)	09:30 - 09:40

Best Abstracts

10:20 - 11:00

Plenary

BA3 - Best abstracts 3

Raffaella Greco (Milano, Italy)

Fabio Ciceri (Milano, Italy)

BA3-1	Rapcabtagene Autoleucel (YTB323) for Patients with First Line High-risk Large B-cell Lymphoma (1L HR LBCL): Phase 2 Interim Results Pere Barba (Barcelona, Spain)	10:20 - 10:30
BA3-2	Targeting ENTPD3 with CAR Tregs for Antigen-specific Immunotherapy in Type 1 Diabetes Tom Pieper (Hannover, Germany)	10:30 - 10:40
BA3-3	A Longitudinal Single-cell Atlas to Predict Outcome and Toxicity after BCMA-directed CAR T Cell Therapy in Multiple Myeloma Michael Rade (Leipzig, Germany)	10:40 - 10:50
BA3-4	Universal Gene-edited CD45CAR T-cells for AML Jenny Yeung (London, United Kingdom)	10:50 - 11:00

Break

11:00 - 11:40

IT

Coffee Break*Best Abstracts*

11:10 - 11:20

IT

EIA02 - Update on 5th Emerging Investigators EBMT-EHA Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy**Synergizing Microbiome-derived postbiotics and CAR T-cell Engineering**

Maik Luu (Würzburg, Germany)

11:10 - 11:20

Physicians Session

11:40 - 12:40

Plenary

PS8 - Myeloma

Hermann Einsele (Würzburg, Germany)

Sonja Zweegman (Amsterdam, Netherlands)

PS8-1	Bispecifics vs CART Paula Rodríguez-Otero (Pamplona, Spain)	11:40 - 12:00
PS8-2	Target finding for MM Arun Wiita (San Francisco, United States)	12:00 - 12:20
PS8-3	Access to therapy in MM Mohamad Mohty (Paris, France)	12:20 - 12:40

Physicians Session

11:40 - 12:40

Breakout

PS9B - Building Alignment in CAR-T Data Collection: From Delphi Consensus to Sustainable Collaboration

Carmen Sanges (Würzburg, Germany)

Jürgen Kuball (Utrecht, Netherlands)

PS9B-1	Overview, T2EVOLVE-GoCART harmonisation efforts, objectives of session, introduction of working group Carmen Sanges (Würzburg, Germany)	11:40 - 11:45
PS9B-2	From Consensus to Implementation: Results of the Delphi Survey	11:45 - 11:55

	Jürgen Kuball (Utrecht, Netherlands)	
PS9B-3	EBMT Registry Perspective Steffie Van der Werf (Leiden, Netherlands)	11:55 - 12:05
PS9B-4	National Experience: Austrian OMOP Integration Maria Quaranta (Luxemburg, Luxembourg)	12:05 - 12:15
PS9B-5	CERTAINTY Project and Future Outlook Kristin Reiche (Leipzig, Germany)	12:15 - 12:25
PSB9-6	Panel discussion, Q&A and closing remarks Carmen Sanges (Würzburg, Germany) Jürgen Kuball (Utrecht, Netherlands) Steffie Van der Werf (Leiden, Netherlands) Kristin Reiche (Leipzig, Germany) Maria Quaranta (Luxemburg, Luxembourg)	12:25 - 12:40
<i>Physicians Session</i> 12:55 - 14:00		Breakout
CL - Closing Ceremony, Best abstracts & Awards		
Annalisa Ruggeri (Milan, Italy) Maria Themeli (Amsterdam, Netherlands)		
BAA-1	Seroprotection against Vaccine-preventable Infections Is Inferior at Baseline and Remains Diminished in BCMA- Compared to CD19-CAR T Recipients Giulia Magno (Munich, Germany)	12:55 - 13:05
BAA-2	CART Cells Targeting the Immunosuppressive Bone-Marrow Microenvironment to Successfully Combat Resistance in Multiple Myeloma Jennifer Meyer Feigin (Rochester, United States)	13:05 - 13:15
BAA-3	Selective Targeting of T-Cell Malignancies Using a TRBC1-Directed CAR T-Cell Therapy Anna De Lucia (Meldola, Italy)	13:15 - 13:25
BAA-4	Direct in vivo CAR T Cell Engineering via a T-cell-Tropic AAV-transposon Platform Mobina Ostadiasrami (Würzburg, Germany)	13:25 - 13:35
BAA-6	Updated Results from a Phase I Trial of CD19/CD22 BiCistronic CAR T-cells in Children, Adolescents, and Young Adults with Recurrent or Refractory B-cell ALL Alexandra Dreyzin (Bethesda, United States)	13:35 - 13:45
BAA-7	Awards & Closing Remarks Maria Themeli (Amsterdam, Netherlands) Annalisa Ruggeri (Milan, Italy)	13:45 - 14:00